These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7831665)

  • 61. Binding of platelet factor 4 to heparin oligosaccharides.
    Denton J; Lane DA; Thunberg L; Slater AM; Lindahl U
    Biochem J; 1983 Feb; 209(2):455-60. PubMed ID: 6847629
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reproducibility of the anti-Factor Xa and anti-Factor IIa assays applied to enoxaparin solution.
    Martinez C; Savadogo A; Agut C; Anger P
    J Pharm Biomed Anal; 2013; 81-82():138-45. PubMed ID: 23644908
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers.
    Laforest MD; Colas-Linhart N; Guiraud-Vitaux F; Bok B; Bara L; Samama M; Marin J; Imbault F; Uzan A
    Br J Haematol; 1991 Feb; 77(2):201-8. PubMed ID: 1848441
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components.
    Mourier PAJ; Herman F; Sizun P; Viskov C
    J Pharm Biomed Anal; 2016 Sep; 129():542-550. PubMed ID: 27497655
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Development and evaluation of PEGylated Enoxaparin: a novel approach for enhanced anti-Xa activity.
    Choubey AK; Dora CP; Bhatt TD; Gill MS; Suresh S
    Bioorg Chem; 2014 Jun; 54():1-6. PubMed ID: 24681308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of the biological activity of 2 formulations of enoxaparin in 12 healthy volunteers.
    Sharma V; Madhu S; Natarajan P; Muniyandi G; Jaiswal V; Saxena R
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):387-93. PubMed ID: 19671565
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin.
    Patel RP; Narkowicz C; Jacobson GA
    J Pharm Sci; 2009 May; 98(5):1700-11. PubMed ID: 18979533
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects.
    Falkon L; Garí M; Sáenz-Campos D; Antonijoan R; Barbanoj M; Fontcuberta J
    Thromb Haemost; 1995 Apr; 73(4):728-9. PubMed ID: 7495089
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method.
    Emanuele RM; Racanelli A; Fareed J
    Ther Drug Monit; 1988; 10(2):153-9. PubMed ID: 3164149
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma.
    Schmidt M; Barrowcliffe TW; Gray E; Watton J; Harenberg J
    Thromb Res; 1991 Sep; 63(5):503-8. PubMed ID: 1755003
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Heparin fractions with high and low affinities to antithrombin III are cleared at different rates.
    Caranobe C; Petitou M; Dupouy D; Gabaig AM; Sié P; Buchanan MR; Boneu B
    Thromb Res; 1986 Sep; 43(6):635-41. PubMed ID: 3764809
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin.
    Baytas SN; Varghese SS; Jin W; Yu Y; He P; Douaisi M; Zhang F; Brodfuehrer P; Xia K; Dordick JS; Linhardt RJ
    J Med Chem; 2021 Feb; 64(4):2242-2253. PubMed ID: 33586962
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Relative activities of heparin fractions obtained by gel chromatography.
    Graham DT; Pomeroy AR
    Thromb Haemost; 1980 Feb; 42(5):1598-603. PubMed ID: 7368160
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of pro- and anti-proliferative oligosaccharides of heparins.
    Lean QY; Patel RP; Stewart N; Sohal SS; Gueven N
    Integr Biol (Camb); 2014 Jan; 6(1):90-9. PubMed ID: 24310794
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative Analysis of Two Enoxaparin Sodium Drugs by Heptest.
    Berkovskii AL; Sergeeva EV; Chernobrovkin MG; Zinchenko AV
    Pharm Chem J; 2023; 56(10):1407-1410. PubMed ID: 36683826
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anticoagulant profile of subcutaneous enoxaparin in healthy dogs.
    Frum J; Havill K; Andrews C; Langston C; Brooks MB; Archer T; Mackin A; Thomason J
    J Vet Pharmacol Ther; 2022 Jan; 45(1):34-45. PubMed ID: 34622463
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.
    Casele HL; Laifer SA; Woelkers DA; Venkataramanan R
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 1):1113-7. PubMed ID: 10561628
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cross-interference of rivaroxaban and enoxaparin on Berichrom anti-Xa heparin and Biophen direct Xa inhibitor assays.
    Wong WH; Kaur H; Tan CW; Lee LH; Ng HJ
    Int J Lab Hematol; 2018 Aug; 40(4):e63-e65. PubMed ID: 29663719
    [No Abstract]   [Full Text] [Related]  

  • 79. Molecular weight dependence of the anticoagulant properties of heparin: intravenous and subcutaneous administration of fractionated heparins to man.
    Lane DA; MacGregor IR; VanRoss M; Cella G; Kakkar VV
    Thromb Res; 1979; 16(5-6):651-62. PubMed ID: 524315
    [No Abstract]   [Full Text] [Related]  

  • 80. Extraction methods of glycosaminoglycans from biologic fluids.
    Bianchini P; Mascellani G; Osima B; Parma B; Bergonzini G; Giusti P
    Semin Thromb Hemost; 1994; 20(2):205-13. PubMed ID: 7997892
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.